DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2004/0101523 A1 Reitz Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2004/0101523 A1 Reitz Et Al US 2004O1 O1523A1. (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0101523 A1 Reitz et al. (43) Pub. Date: May 27, 2004 (54) RENAL-SELECTIVE PRODRUGS FOR Publication Classification CONTROL OF RENAL SMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF (51) Int. Cl. ............................. A61K 38/43; C12N 9/99 HYPERTENSION (52) U.S. Cl. ........................................... 424/94.1; 435/184 (75) Inventors: David B. Reitz, Chesterfield, MO (US); John P. Koepke, St. Louis, MO (US); (57) ABSTRACT Edward H. Blaine, University City, MO (US); Joseph R. Schuh, St. Louis, MO (US); Robert E. Manning, St. Renal-Selective prodrugs are described which are preferen Louis, MO (US); Glenn J. Smits, tially converted in the kidney to compounds capable of Ellisville, MO (US) inhibiting Synthesis of catecholamine-type neurotransmit ters involved in renal Sympathetic nerve activity. The pro drugs described herein are derived from inhibitor com Correspondence Address: pounds capable of inhibiting one or more of the enzymes J. Timothy Keane involved in catecholamine Synthesis, Such compounds being PHARMACIA CORPORATION of Pfizer Inc., classifiable as tyrosine hydroxylase inhibitors, or as dopa Corporate Patent Department decarboxylase inhibitors, or as dopamine-B-hydroxylase P.O. BOX 1027 inhibitors. These inhibitor compounds are linked to a chemi Chesterfield, MO 63006 (US) cal moiety, Such as a glutamic acid derivative, by a cleavable bond which is recognized Selectively by enzymes located predominantly in the kidney. The liberated inhibitor com (73) Assignee: G.D. Searle & Co., Chicago, IL pound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine Synthesis. Inhi (21) Appl. No.: 10/689,919 bition of renal catecholamine Synthesis can Suppress height ened renal nerve activity associated with Sodium-retention (22) Filed: Oct. 20, 2003 related disorderS Such as hypertension. Conjugates of par Related U.S. Application Data ticular interest are glutamyl derivatives of dopamine-B- hydroxylase inhibitors, of which N-acetyl-y-glutamyl (63) Continuation of application No. 10/151,211, filed on fusaric acid hydrazide (shown below) is preferred. May 20, 2002, now abandoned, which is a continu ation of application No. 09/678,015, filed on Oct. 2, 2000, now abandoned, which is a continuation of N application No. 09/444,888, filed on Nov. 22, 1999, O O CO2H now abandoned, which is a continuation of applica 2n tion No. 08/639,493, filed on Apr. 29, 1996, now N C-N-N-C-CH-CH-CH abandoned, which is a continuation of application No. 08/280,170, filed on Jul. 25, 1994, now abandoned, H. H. -n which is a continuation-in-part of application No. =o PCT/US90/04168, filed on Jul 25, 1990, which is a CH continuation-in-part of application No. 07/386,527, filed on Jul. 27, 1989, now abandoned. Patent Application Publication May 27, 2004 Sheet 1 of 16 US 2004/0101523 A1 Acute In Vivo Effects of Vehicle and Example #3 Conjugate 100 8 O 6 O 4. O -o- vehicle -O- Example #3 2 O O 1S 30 4S 60 Time (minutes) Figure 1 Patent Application Publication May 27, 2004 Sheet 2 of 16 US 2004/0101523 A1 Acute In Vivo Effects of Example #3 Conjugate s-O- Vehicle -O- Example #3 Conjugate O 5 30 4S 60 Tine (minutes) Patent Application Publication May 27, 2004 Sheet 3 of 16 US 2004/0101523 A1 Chronic Infusion of Example #464 Conjugate 2OO Or Vehicle -O- Example #464 Conjugate 190 18O 170 160 150 Time (days) Figure 3 Patent Application Publication May 27, 2004 Sheet 4 of 16 US 2004/0101523 A1 Formation of Fusaric Acid From Example #859 Conjugate by Rat Kidney Homogenate 34.5 2 O O 20 30 40 50 Tine (hours) Patent Application Publication May 27, 2004 Sheet 5 of 16 US 2004/0101523 A1 Enzymatic Formation of Fusaric Acid From Example #859 Conjugate 20 15 O S O 20 40 60 80 OO 120 1 40 Time (hours) Patent Application Publication May 27, 2004 Sheet 6 of 16 US 2004/0101523 A1 Effect of Fusaric Acid and Example #859 Conjugate on Dopamine-6-Hydroxylase Activity In Vitro 0.6 as e N 0.5 2 s - 0. s S. S 03 O2 s s 0.1 -O Fusaric Acid 0.0 -O- Example #859 Conjugate .0 ... 1 10 100 Concentration (M) Figure 6 Patent Application Publication May 27, 2004 Sheet 7 of 16 US 2004/0101523 A1 Dopamine-?3-Hydroxylase Inhibition by Exampie #859 Conjugate and Related Compounds 1 OO Example #859 Conjugate Example #858 Conjugate QP Fusaric Acid Hydrazide us Fusaic Acid Ne 6 O 40 20 Test Compound (20 M) Figure 7 Patent Application Publication May 27, 2004 Sheet 8 of 16 US 2004/0101523 A1 Acute In Vivo Effects of Fusaric Acid or Example #859 Conjugate on Mean Arterial Pressure 18O 160 140 -O- Fusaic Acid -o- Example #859 Conjugate 120 OO 8 O O S 30 4S 60 Tine (minutes) Patent Application Publication May 27, 2004 Sheet 9 of 16 US 2004/0101523 A1 Acute In Vivo Effects of Fusaric Acid and Example #859 Conjugate on Renal Blood Flow TO Fusaric Acid 5 mO Example #859 Conjugate 4. O S 3O 4S 60 Tine (minutes) Patent Application Publication May 27, 2004 Sheet 10 of 16 US 2004/0101523 A1 Chronic In Vivo Effects of Saline, Fusaric Acid and Example #859 Conjugate 200 180 s Vehicle On Fusaric Acid -O-Example #859 Conjugate 160 140 20 100 O 2 3 4 S 6 Time (days) Figure 10 Patent Application Publication May 27, 2004 Sheet 11 of 16 US 2004/0101523 A1 Chronic Infusion of Example #863 Conjugate Or Vehicle 8 O -O- Example #863 Conjugate 170 160 150 140 O 2 3 4 Time (days) Figure 11 Patent Application Publication May 27, 2004 Sheet 12 of 16 US 2004/0101523 A1 Heart Norepinephrine Levels Following 5 Day Infusion of Vehicle, Fusaric Acid, and Example #859 Conjugate 3OOO 2OOO 1 OOO Vehicle Fusaric Acid Example #859 Conjugate Patent Application Publication May 27, 2004 Sheet 13 of 16 US 2004/0101523 A1 Kidney Norepinephrine Levels Following S Day Infusion of Vehicle, Fusaric Acid, and Example #859 Conjugate 1 OOO 68 20 O Vehicle Fusaric Acid ExampleConjugate #859 Figure 13 Patent Application Publication May 27, 2004 Sheet 14 of 16 US 2004/0101523 A1 Mean Arterial Pressure Response to Example #859 Conjugate after I.V. Injection in Dogs 200 Vehicle a 7 mg/kg 150 D 60 mg/kg 125 2 OO % 75 2 50 2% 2 O 2 3 Time (hours) FIGURE 14 Patent Application Publication May 27, 2004 Sheet 15 of 16 US 2004/0101523 A1 Renal Blood Flow Response to Example #859 Conjugate after I.V. Injection in Dogs 200 Vehicle 175 a 7 mg/kg B 20 mg/kg 150 D 60 mg/kg 125 OO 75 50 25 0 1. |2 3 Time (hours) FIGURE 15 Patent Application Publication May 27, 2004 Sheet 16 of 16 US 2004/0101523 A1 Effects of Ex. 859 in DOCA Hypertensive Micropigs 180 -OH vehicleEXAMPLE 200 #859 m/day 5 mg/kg 5 n=3 160 150 140 30 20 110 100 1. 2 3. 4 Time (days) FIGURE 16 US 2004/0101523 A1 May 27, 2004 RENAL-SELECTIVE PRODRUGS FOR CONTROL neys may be an effective therapeutic treatment for chronic OF RENAL SMPATHETIC NERVE ACTIVITY IN Sodium-retaining disorders, Such as hypertension, conges THE TREATMENT OF HYPERTENSION tive heart failure, cirrhosis, and nephrosis. RELATED APPLICATION 0006. One approach to reduce sympathetic nervous sys tem effects on renal function is to inhibit the synthesis of one 0001. This application is a continuation-in-part of U.S. or more compounds involved as intermediates in the "cat Application Ser. No. PCT/US90/04168 filed 25 Jul. 1990, echolamine cascade', that is, the pathway involved in Syn which is a continuation-in-part of U.S. application Ser. No. thesis of the neurotransmitter norepinephrine. Stepwise, 07/386,527 filed 27 Jul 1989. these catecholamines are Synthesized in the following man ner: (1) tyrosine is converted to dopa by the enzyme tyrosine FIELD OF THE INVENTION hydroxylase; (2) dopa is converted to dopamine by the 0002 This invention is in the field of cardiovascular enzyme dopa decarboxylase; and (3) dopamine is converted therapeutics and relates to a class of compounds useful in to norepinephrine by the enzyme dopamine-B-hydroxylase. control of hypertension. Of particular interest is a class of Inhibition of dopamine-B-hydroxylase activity, in particular, compounds which prevent or control hypertension by Selec would increase the renal vasodilatory, diuretic and natri tive action on the renal Sympathetic nervous System. uretic effects due to dopamine. Inhibition of the action of any of these enzymes would decrease the renal vasocon Strictive, antidiuretic and antinatriuretic effects of norepi BACKGROUND OF THE INVENTION nephrine. Therapeutically, these effects oppose chronic 0.003 Hypertension has been linked to increased sympa Sodium retention. thetic nervous System activity Stimulated through any of four mechanisms, namely (1) by increased vascular resistance, 0007 Many compounds are known to inhibit the action (2) by increased cardiac rate, Stroke Volume and output, (3) of the catecholamine-cascade-converting enzymes. For by vascular muscle defects or (4) by Sodium retention and example, the compound C.-methyltyrosine inhibits the action renin release J. P. Koepke et al, The Kidney in Hyperten of the enzyme tyrosine hydroxylase. The compound C.-me Sion, B. M. Brenner and J. H. Laragh (Editors), Vol. 1, p. 53 thyldopa inhibits the action of the enzyme dopa-decarboxy (1987). As to this fourth mechanism in particular, stimula lase, and the compound fuSaric acid inhibits the action of tion of the renal Sympathetic nervous System can affect renal dopamine-B-hydroxylase.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al
    US 20130253 056A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas et al. (43) Pub. Date: Sep. 26, 2013 (54) CONTINUOUS ADMINISTRATION OF (60) Provisional application No. 61/179,511, filed on May LEVODOPA AND/OR DOPA 19, 2009. DECARBOXYLASE INHIBITORS AND COMPOSITIONS FOR SAME Publication Classification (71) Applicant: NEURODERM, LTD., Ness-Ziona (IL) (51) Int. Cl. A63L/216 (2006.01) (72) Inventors: Mara Nemas, Gedera (IL); Oron (52) U.S. Cl. Yacoby-Zeevi, Moshav Bitsaron (IL) CPC .................................... A6 IK3I/216 (2013.01) USPC .......................................................... 514/538 (73) Assignee: Neuroderm, Ltd., Ness-Ziona (IL) (57) ABSTRACT (21) Appl. No.: 13/796,232 Disclosed herein are for example, liquid aqueous composi (22) Filed: Mar 12, 2013 tions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neuro Related U.S. Application Data logical or movement diseases or disorders such as restless leg (63) Continuation-in-part of application No. 12/961,534, syndrome, Parkinson's disease, secondary parkinsonism, filed on Dec. 7, 2010, which is a continuation of appli Huntington's disease, Parkinson's like syndrome, PSP. MSA, cation No. 12/836,130, filed on Jul. 14, 2010, now Pat. ALS, Shy-Drager syndrome, dystonia, and conditions result No. 7,863.336, which is a continuation of application ing from brain injury including carbon monoxide or manga No. 12/781,357, filed on May 17, 2010, now Pat. No. nese intoxication, using Substantially continuous administra 8,193,243. tion of levodopa and/or carbidopa or ester and/or salt thereof.
    [Show full text]
  • Screening of a Composite Library of Clinically Used Drugs and Well
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Pharmacol Manuscript Author Res. Author Manuscript Author manuscript; available in PMC 2017 November 01. Published in final edited form as: Pharmacol Res. 2016 November ; 113(Pt A): 18–37. doi:10.1016/j.phrs.2016.08.016. Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer Nadiya Druzhynaa, Bartosz Szczesnya, Gabor Olaha, Katalin Módisa,b, Antonia Asimakopoulouc,d, Athanasia Pavlidoue, Petra Szoleczkya, Domokos Geröa, Kazunori Yanagia, Gabor Töröa, Isabel López-Garcíaa, Vassilios Myrianthopoulose, Emmanuel Mikrose, John R. Zatarainb, Celia Chaob, Andreas Papapetropoulosd,e, Mark R. Hellmichb,f, and Csaba Szaboa,f,* aDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, TX, USA bDepartment of Surgery, The University of Texas Medical Branch, Galveston, TX, USA cLaboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece dCenter of Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens, Greece eNational and Kapodistrian University of Athens, School of Pharmacy, Athens, Greece fCBS Therapeutics Inc., Galveston, TX, USA Abstract Cystathionine-β-synthase (CBS) has been recently identified as a drug target for several forms of cancer. Currently no
    [Show full text]
  • Gait Analysis in Advanced Parkinson's Disease – Effect of Levodopa And
    ORIGINAL ARTICLE Gait Analysis in Advanced Parkinson’s Disease – Effect of Levodopa and Tolcapone Din-E Shan, Shwn-Jen Lee, Ling-Yi Chao, and Shyh-Ing Yeh ABSTRACT: Objective: To determine the therapeutic effect of levodopa/benserazide and tolcapone on gait in patients with advanced Parkinson’s disease. Methods: Instrumental gait analysis was performed in 38 out of 40 patients with wearing-off phenomenon during a randomized, double-blind, placebo- controlled trial of tolcapone. R e s u l t s : Gait analysis disclosed a significant improvement by levodopa/benserazide in walking speed, stride length and the range of motion of hip, knee and ankle joints. At the end of the study, both the UPDRS motor scores during off-period and the percentage of off time improved significantly using tolcapone. However, gait analysis could not confirm this improvement. With respect to levodopa/benserazide effect, the reduction in rigidity correlated with improved angular excursion of the ankle, whereas the decreased bradykinesia correlated with improved stride length and angular excursion of the hip and knee joints. Conclusion: The results of our gait analysis confirmed that in parkinsonian patients with fluctuating motor symptoms levodopa/benserazide, but not tolcapone, produced a substantial improvement. RÉSUMÉ: Analyse de la démarche chez les patients en phase avancée de la maladie de Parkinson – Effet de la lévodopa et du tolcapone. Objectif: Le but de cette étude était de déterminer l’effet thérapeutique de la lévodopa/bensérazide et du tolcapone sur la démarche, chez les patients en phase avancée de la maladie de Parkinson. Méthodes: Une analyse instrumentale de la démarche a été réalisée chez 38 de 40 patients ayant un phénomène de détérioration de fin de dose pendant un essai randomisé, en double insu, contrôlé par placebo, du tolcapone.
    [Show full text]
  • PSP: Some Answers
    PSP: Some Answers Lawrence I. Golbe, MD Professor of Neurology, Rutgers Robert Wood Johnson Medical School Director of Clinical Affairs and Scientific Advisory Board Chairman, CurePSP October 2017 What is Progressive Supranuclear Palsy (PSP)? Of the approximately five to seven of every 100,000 people in Canada with progressive supranuclear palsy (PSP), few, if any, had ever heard of the disease before their diagnosis. In fact, most patients with PSP report that their family doctors knew nothing about it until a neurologist made the diagnosis. As of now, three of every four people with a diagnosis of PSP could have been diagnosed earlier, if their doctor had suspected it and performed the appropriate examination. However, it is appearing in medical journals more and more often, which will help doctors become familiar with PSP. This pamphlet should help patients and their families do the same. Why has no one heard of PSP? PSP is rare: no one even realized it existed until 1963, when several patients were first described at a national neurology research convention and the disease was given its name. In retrospect, at least 12 cases of PSP had appeared in the medical literature between 1909 and 1962, but because of its resemblance to Parkinson’s, it wasn’t recognized as a distinct disease. The brain under the microscope is almost identical to that of “post-encephalitic parkinsonism,” a common condition in the early 20th century but now nearly extinct, which also made for erroneous diagnoses during that era. Although PSP is slightly more common than the well-known amyotrophic lateral sclerosis (called ALS, or Lou Gehrig’s disease in the U.S.
    [Show full text]
  • Carbidopa and Levodopa | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Carbidopa and Levodopa This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Duopa; Rytary; Sinemet; Sinemet CR [DSC] Brand Names: Canada AA-Levocarb CR; APO-Levocarb; APO-Levocarb 100/25; APO-Levocarb 250/25; DOM-Levo-Carbidopa; Duodopa; MINT-Levocarb; PMS-Levocarb CR; Pro-Lecarb; PRO-Levocarb-100/25 [DSC]; Sinemet 100/25; Sinemet 250/25; Sinemet CR 200/50 [DSC]; Sinemet CR [DSC]; TEVA-Levocarbidopa What is this drug used for? It is used to treat Parkinson’s disease. It is used to treat signs like Parkinson’s disease caused by other health problems. It may be given to you for other reasons. Talk with the doctor. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Glaucoma, a skin lump or growth, or a history of skin cancer. Carbidopa and Levodopa 1/10 If you are taking any of these drugs: Reserpine or tetrabenazine. If you are taking any of these drugs: Linezolid or methylene blue. If you have taken certain drugs for depression or Parkinson’s disease in the last 14 days. This includes isocarboxazid, phenelzine, tranylcypromine, selegiline, or rasagiline. Very high blood pressure may happen.
    [Show full text]
  • Dopamine: a Role in the Pathogenesis and Treatment of Hypertension
    Journal of Human Hypertension (2000) 14, Suppl 1, S47–S50 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh Dopamine: a role in the pathogenesis and treatment of hypertension MB Murphy Department of Pharmacology and Therapeutics, National University of Ireland, Cork, Ireland The catecholamine dopamine (DA), activates two dis- (largely nausea and orthostasis) have precluded wide tinct classes of DA-specific receptors in the cardio- use of D2 agonists. In contrast, the D1 selective agonist vascular system and kidney—each capable of influenc- fenoldopam has been licensed for the parenteral treat- ing systemic blood pressure. D1 receptors on vascular ment of severe hypertension. Apart from inducing sys- smooth muscle cells mediate vasodilation, while on temic vasodilation it induces a diuresis and natriuresis, renal tubular cells they modulate sodium excretion. D2 enhanced renal blood flow, and a small increment in receptors on pre-synaptic nerve terminals influence nor- glomerular filtration rate. Evidence is emerging that adrenaline release and, consequently, heart rate and abnormalities in DA production, or in signal transduc- vascular resistance. Activation of both, by low dose DA tion of the D1 receptor in renal proximal tubules, may lowers blood pressure. While DA also binds to alpha- result in salt retention and high blood pressure in some and beta-adrenoceptors, selective agonists at both DA humans and in several animal models of hypertension. receptor classes have been studied in the treatment of
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Hypertensive Crises 8.25
    Hypertensive Crises 8.25 Hypertension crises secondary to monoamine oxidase inhibitor–tyramine interactions Monoamine oxidase inhibitor therapy Impaired degradation of intracellular amines Ingestion of (epinephrine, norepinephrine, dopamine) tyramine-containing food Accumulation of catecholamines in Hepatic monamine nerve terminal storage granules oxidase inhibition with decreased Increased circulating oxidative metabolism tyramine level of tyramine Massive release of catecholamines Tachyarrhythmias Vasoconstriction (increased systemic vascular resistance) Severe paroxysm of hypertension Hypertensive encephalopathy Acute hypertensive heart failure with pulmonary edema Intracerebral hemorrhage (Fig. 8-21) (Figs. 8-24 and 8-25) FIGURE 8-32 Hypertensive crises secondary to monoamine oxidase inhibitor–tyramine interactions. Severe paroxysmal hypertension complicated by intracerebral or subarachnoid hemorrhage, hypertensive encephalopathy, or acute hypertensive heart failure can occur in patients treated with monoamine oxidase (MOA) inhibitors after ingestion of certain drugs or tyramine- containing foods [48,49]. Because MAO is required for degradation of intracellular amines, including epinephrine, norepinephrine, and dopamine, MAO inhibitors lead to accumulation of catecholamines within storage granules in nerve terminals. The amino acid tyramine is a potent inducer of neurotransmitter release from nerve terminals. As a result of inhibition of hepatic MAO, ingested tyramine escapes oxidative degradation in the liver. In addition, the high circulating levels of tyramine provoke massive catecholamine release from nerve terminals, resulting in vasoconstriction and a paroxysm of severe hypertension. A hyper- adrenergic syndrome resembling pheochromocytoma then ensues. Symptoms include severe pounding headache, flushing or pallor, profuse diaphoresis, nausea, vomiting, and extreme prostration. The mean increase in blood pressure is 55 mm Hg systolic and 30 mm Hg diastolic [49]. The duration of the attacks varies from 10 minutes to 6 hours.
    [Show full text]
  • 210913Orig1s000 CLINICAL PHARMACOLOGY REVIEW(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210913Orig1s000 CLINICAL PHARMACOLOGY REVIEW(S) Office of Clinical Pharmacology Review NDA Number 212489 Link to EDR \\cdsesub1\evsprod\nda212489 Submission Date 04/26/2019 Submission Type 505(b)(1) NME NDA (Standard Review) Brand Name ONGENTYS Generic Name opicapone Dosage Form/Strength and Capsules: 25 mg and 50 mg Dosing Regimen 50 mg administered orally once daily at bedtime Route of Administration Oral Proposed Indication Adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s Disease experiencing “OFF” episodes Applicant Neurocrine Biosciences, Inc. (NBI) Associated IND IND (b) (4) OCP Review Team Mariam Ahmed, Ph.D. Atul Bhattaram, Ph.D. Sreedharan Sabarinath, Ph.D. OCP Final Signatory Mehul Mehta, Ph.D. 1 Reference ID: 4585182 Table of Contents 1. EXECUTIVE SUMMARY .............................................................................................................................................................. 4 1.1 Recommendations ..................................................................................................................................................... 4 1.2 Post-Marketing Requirements and Commitments ......................................................................................... 6 2. SUMMARY OF CLINICAL PHARMACOLOGY ASSESSMENT ............................................................................................. 6 2.1 Pharmacology and Clinical Pharmacokinetics ..................................................................................................
    [Show full text]
  • Azilect, INN-Rasagiline
    SCIENTIFIC DISCUSSION 1. Introduction AZILECT is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations. Rasagiline is administered orally, at a dose of 1 mg once daily with or without levodopa. Parkinson’s disease is a common neurodegenerative disorder typified by loss of dopaminergic neurones from the basal ganglia, and by a characteristic clinical syndrome with cardinal physical signs of resting tremor, bradikinesia and rigidity. The main treatment aims at alleviating symptoms through a balance of anti-cholinergic and dopaminergic drugs. Parkinson’s disease (PD) treatment is complex due to the progressive nature of the disease, and the array of motor and non-motor features combined with early and late side effects associated with therapeutic interventions. Rasagiline is a chemical inhibitor of the enzyme monoamine oxidase (MAO) type B which has a major role in the inactivation of biogenic and diet-derived amines in the central nervous system. MAO has two isozymes (types A and B) and type B is responsible for metabolising dopamine in the central nervous system; as dopamine deficiency is the main contributing factor to the clinical manifestations of Parkinson’s disease, inhibition of MAO-B should tend to restore dopamine levels towards normal values and this improve the condition. Rasagiline was developed for the symptomatic treatment of Parkinson’s disease both as monotherapy in early disease and as adjunct therapy to levodopa + aminoacids decarboxylase inhibitor (LD + ADI) in patients with motor fluctuations. 2. Quality Introduction Drug Substance • Composition AZILECT contains rasagiline mesylate as the active substance.
    [Show full text]
  • Compositions for Continuous Administration of Dopa
    (19) TZZ ¥ _T (11) EP 2 432 454 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/08 (2006.01) A61K 9/10 (2006.01) 01.03.2017 Bulletin 2017/09 A61K 31/198 (2006.01) A61P 25/16 (2006.01) (21) Application number: 10725880.8 (86) International application number: PCT/IL2010/000400 (22) Date of filing: 17.05.2010 (87) International publication number: WO 2010/134074 (25.11.2010 Gazette 2010/47) (54) COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA DECARBOXYLASE INHIBITORS ZUSAMMENSETZUNGEN FÜR DIE KONTINUIERLICHE VERABREICHUNG VON DOPA-DECARBOXYLASEHEMMERN COMPOSITIONS POUR ADMINISTRATION CONTINUE D’UN INHIBITEUR DE LA DOPA-DÉCARBOXYLASE (84) Designated Contracting States: (74) Representative: ABG Patentes, S.L. et al AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Avenida de Burgos, 16D GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Edificio Euromor PL PT RO SE SI SK SM TR 28036 Madrid (ES) (30) Priority: 19.05.2009 US 179511 P (56) References cited: WO-A1-2006/006929 US-A- 4 409 233 (43) Date of publication of application: 28.03.2012 Bulletin 2012/13 • NYHOLM D: "Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations (73) Proprietor: Neuroderm Ltd and dyskinesias in advanced Parkinson’s 74036 Ness Ziona (IL) disease" EXPERT REVIEW OF NEUROTHERAPEUTICS, FUTURE DRUGS, (72) Inventors: LONDON, GB LNKD- • YACOBY-ZEEVI, Oron DOI:10.1586/14737175.6.10.1403, vol. 6, no. 10, 1 60946 Bitsaron (IL) January 2006 (2006-01-01), pages 1403-1411, •NEMAS,Mara XP008082627 ISSN: 1473-7175 70700 Gedera (IL) Remarks: Thefile contains technical information submitted after the application was filed and not included in this specification Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Levodopa-Benserazide.Pdf
    MCore0B Safety Profile Active substance: Levodopa + Benserazide Pharmaceutical form(s)/strength: tablets: 100/25 mg, 200/50 mg dispersible tablets: 50/12.5 mg, 100/25 mg capsules: 50/12.5 mg, 100/25 mg, 200/50 mg, controlled release capsules (HBS): 100/25 mg dual release capsules: 200/50 mg P-RMS: HU/H/PSUR/0031/001 Date of FAR: 18.09.2013 4.3 Contraindications Levodopa-benserazide must not be given to patients with known hypersensitivity to levodopa or benserazide. Levodopa-benserazide must not be given in conjunction with non-selective monoamine oxidase (MAO) inhibitors. However, selective MAO-B inhibitors, such as selegiline and rasagiline or selective MAO-A inhibitors, such as moclobemide, are not contraindicated. Combination of MAO-A and MAO-B inhibitors is equivalent to non-selective MAO inhibition, and hence this combination should not be given concomitantly with levodopa-benserazide (see section 4.5 Interactions with other Medicinal Products and other Forms of Interaction). Levodopa-benserazide must not be given to patients with decompensated endocrine (e.g. phaeochromocytoma, hyperthyroidism, Cushing syndrome), renal (except RLS patients on dialysis) or hepatic function, cardiac disorders (e.g. severe cardiac arrhythmias and cardiac failure), psychiatric diseases with a psychotic component or closed angle glaucoma. Levodopa-benserazide must not be given to patients less than 25 years old (skeletal development must be complete). Levodopa-benserazide must not be given to pregnant women or to women of childbearing potential in the absence of adequate contraception. If pregnancy occurs in a woman taking levodopa-benserazide, the drug must be discontinued (as advised by the prescribing physician).
    [Show full text]